ROBOS '25, The 7th Raab Outer Banks Oncology Symposium: Morning Sessions, July 11

Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis.

Tian H, Wan C.

World J Surg Oncol. 2025 Apr 7;23(1):126. doi: 10.1186/s12957-025-03788-0.

PMID: 40197348 Free PMC article.

2.

Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis.

Yu JH, Han JW, Suh YJ, Chon YE, Kim HY, An JH, Jin YJ, Choi M, Kim SU, Jun DW, Lee HA, Kim MN.

Clin Mol Hepatol. 2024 Sep;30(Suppl):S186-S198. doi: 10.3350/cmh.2024.0366. Epub 2024 Aug 21.

PMID: 39165160 Free PMC article.

3.

Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Xu H, Zhang H, Li B, Chen K, Wei Y.

BMC Cancer. 2024 Aug 14;24(1):1008. doi: 10.1186/s12885-024-12772-y.

PMID: 39143584 Free PMC article.

4.

An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review.

Darmadi D, Sungkar T, Pakpahan C, Surja SS.

Acta Med Acad. 2024 Apr;53(1):46-58. doi: 10.5644/ama2006-124.443.

PMID: 38984699 Free PMC article.

5.

A Network Meta-analysis of the Efficacy of Drug Therapy in First-line Treatment of Advanced Hepatocellular Carcinoma.

Wang X, Peng G, Li J.

J Gastrointestin Liver Dis. 2024 Mar 30;33(1):94-101. doi: 10.15403/jgld-5289.

PMID: 38554414

6.

Effect of intermittent Pringle maneuver on perioperative outcomes and long-term survival following liver resection in patients with hepatocellular carcinoma: a meta-analysis and systemic review.

Hu L, Wang A, Qiao Y, Huang X.

World J Surg Oncol. 2023 Nov 21;21(1):359. doi: 10.1186/s12957-023-03244-x.

PMID: 37986187 Free PMC article.

7.

Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis.

Liu B, Grindrod N, Meyers BM, Freiburger S, Boldt G, Malik A, Jairam MP, Brahmania M, Cardarelli Leite L, Simone CB 2nd, Chow R, Lock M.

Ann Palliat Med. 2023 Nov;12(6):1165-1174. doi: 10.21037/apm-23-463. Epub 2023 Oct 27.

PMID: 37953217

8.

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.

Bae SH, Chun SJ, Chung JH, Kim E, Kang JK, Jang WI, Moon JE, Roquette I, Mirabel X, Kimura T, Ueno M, Su TS, Tree AC, Guckenberger M, Lo SS, Scorsetti M, Slotman BJ, Kotecha R, Sahgal A, Louie AV, Kim MS.

Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):337-351. doi: 10.1016/j.ijrobp.2023.08.015. Epub 2023 Aug 18.

PMID: 37597757 Review.

9.

BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR SYSTEMIC TREATMENT OF HEPATOCELLULAR CARCINOMA.

Chagas AL, Leal CRG, Mello VB, Barros FMDR, Bittencourt PL, Mattos AA, Aroucha D, Fonseca LGD, Silva JRL, Dottori MF, Teixeira R, Mendes LSC, Rezende REF, Filgueira NA, Coutinho AK, Araújo Neto JM, Coelho HSM, Pessoa MG, Cheinquer H, Parise ER, França A, Álvares-DA-Silva MR, Carrilho FJ, Coral GP, Pinto PTA, Pereira LMMB, Paraná R, Alves RCP, Brandão-Mello CE.

Arq Gastroenterol. 2023 Jan-Mar;60(1):106-131. doi: 10.1590/S0004-2803.202301000-14.

PMID: 37194769

10.

Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis.

Yang S, Zhou Y, Zeng L.

Adv Clin Exp Med. 2023 Aug;32(8):839-845. doi: 10.17219/acem/158488.

PMID: 37140014

11.

Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Griffiths CD, Zhang B, Tywonek K, Meyers BM, Serrano PE.

JAMA Netw Open. 2022 Jul 1;5(7):e2222721. doi: 10.1001/jamanetworkopen.2022.22721.

PMID: 35849393 Free PMC article.

12.

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review.

Zhang L, Sun J, Wang K, Zhao H, Zhang X, Ren Z.

Curr Oncol. 2022 Sep 30;29(10):7305-7326. doi: 10.3390/curroncol29100575.

PMID: 36290852 Free PMC article. Review.

13.

Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.

Li L, Li X, Li W, Ding X, Zhang Y, Chen J, Li W.

BMC Cancer. 2022 Jul 9;22(1):750. doi: 10.1186/s12885-022-09841-5.

PMID: 35810271 Free PMC article.

14.

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.

Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J.

Front Immunol. 2022 May 23;13:913464. doi: 10.3389/fimmu.2022.913464. eCollection 2022.

PMID: 35677059 Free PMC article.

15.

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.

Jácome AA, Castro ACG, Vasconcelos JPS, Silva MHCR, Lessa MAO, Moraes ED, Andrade AC, Lima FMT, Farias JPF, Gil RA, Prolla G, Garicochea B.

JAMA Netw Open. 2021 Dec 1;4(12):e2136128. doi: 10.1001/jamanetworkopen.2021.36128.

PMID: 34870682 Free PMC article.

16.

Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review.

Yang DS, Park S, Rim CH, Yoon WS, Shin IS, Lee HA.

Medicina (Kaunas). 2021 Sep 22;57(10):1000. doi: 10.3390/medicina57101000.

PMID: 34684036 Free PMC article. Review.

17.

Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes.

Xie Y, Tian H, Xiang B, Zhang Y, Liu J, Cai Z, Xiang H.

Medicine (Baltimore). 2021 Aug 20;100(33):e26958. doi: 10.1097/MD.0000000000026958.

PMID: 34414963 Free PMC article.

18.

Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma.

Harding-Theobald E, Louissaint J, Maraj B, Cuaresma E, Townsend W, Mendiratta-Lala M, Singal AG, Su GL, Lok AS, Parikh ND.

Aliment Pharmacol Ther. 2021 Oct;54(7):890-901. doi: 10.1111/apt.16563. Epub 2021 Aug 12.

PMID: 34390014 Free PMC article. Review.

19.

Prognostic role of artificial intelligence among patients with hepatocellular cancer: A systematic review.

Lai Q, Spoletini G, Mennini G, Laureiro ZL, Tsilimigras DI, Pawlik TM, Rossi M.

World J Gastroenterol. 2020 Nov 14;26(42):6679-6688. doi: 10.3748/wjg.v26.i42.6679.

PMID: 33268955 Free PMC article.

20.

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.

Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T.

JAMA Oncol. 2020 Dec 1;6(12):e204930. doi: 10.1001/jamaoncol.2020.4930. Epub 2020 Dec 10.

PMID: 33090186 Free PMC article.

21.

Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.

Lim H, Ramjeesingh R, Liu D, Tam VC, Knox JJ, Card PB, Meyers BM.

J Natl Cancer Inst. 2021 Feb 1;113(2):123-136. doi: 10.1093/jnci/djaa119.

PMID: 32898239 Free PMC article.

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma.

da Fonseca LG, Piñero F, Anders M, Bermudez C, Demirdjian E, Varón A, Perez D, Rodriguez J, Beltrán O, Ridruejo E, Caballini P, Araujo A, Florez JDT, Marín JI, Villa M, Orozco F, Poniachik J, Marciano S, Bessone F, Mendizabal M.

Oncotarget. 2025 May 19;16:348-360. doi: 10.18632/oncotarget.28721.

PMID: 40387836 Free PMC article.

2.

Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma.

Jiang Y, Dong X, Zhang Y, Su F, Zhao L, Shi X, Zhong J.

Clin Exp Med. 2025 May 18;25(1):169. doi: 10.1007/s10238-025-01698-9.

PMID: 40382739 Free PMC article. Review.

3.

A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection.

Cheng Y, Gong Y, Li X, Zeng F, Liu B, Chen W, Zhang F, Chen H, Zhu W, Li H, Zhou L, Wu T, Zhou W.

J Nanobiotechnology. 2025 May 16;23(1):353. doi: 10.1186/s12951-025-03424-9.

PMID: 40380326 Free PMC article.

4.

Platelet-albumin-bilirubin versus albumin-bilirubin as a predictor of long-term survival for hepatitis B-Induced hepatocellular carcinoma after hepatic resection.

Yang H, Shen S, Yang Y, Zhou H, Xiang B.

BMC Cancer. 2025 May 12;25(1):855. doi: 10.1186/s12885-025-14240-7.

PMID: 40355826 Free PMC article.

5.

Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria.

Ling S, Yu J, Zhan Q, Gao M, Liu P, Wu Y, Zhang L, Shan Q, Liu H, Wang J, Cai S, Zhou W, Que Q, Wang S, Hong J, Xiang J, Xu S, Liu J, Peng X, Wang N, Wang W, Xie H, Cai J, Wang L, Zheng S, Xu X.

Nat Commun. 2025 May 12;16(1):4392. doi: 10.1038/s41467-025-59745-8.

PMID: 40355422 Free PMC article.

6.

Resection and partial liver transplantation from deceased donors with delayed total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national, multicenter, non-randomized, prospective trial.

Peloso A, Pietrasz D, Daillier E, Cylly L, Scatton O, Goumard C, Mabrut JY, Mohkam K, Lesurtel M, Dokmak S, Jeddou H, Boudjema K, Allard MA, Adam R, Sa Cunha A, Azoulay D, Cherqui D, Vibert E, Golse N.

BMC Cancer. 2025 May 9;25(1):848. doi: 10.1186/s12885-025-14127-7.

PMID: 40346479 Free PMC article.

7.

Meta-analysis of multimodal analgesia for reducing postoperative wound pain after hepatectomy for hepatocellular carcinoma.

Cao Y, Shen J.

Sci Rep. 2025 May 3;15(1):15494. doi: 10.1038/s41598-025-00069-4.

PMID: 40319048 Free PMC article.

8.

Vision transformer-based model can optimize curative-intent treatment for patients with recurrent hepatocellular carcinoma.

Zhang K, Ru J, Wang W, Ma Q, Gao F, Wu J, Dai Z, Xie Q, Mu L, Zhang H, Pan J, Xie L, Zhao Q, Tian J, Yu J, Liang P, Wu H, Li K, Yang W, Wang K, Jiang T.

Nat Commun. 2025 May 1;16(1):4081. doi: 10.1038/s41467-025-59197-0.

PMID: 40312376 Free PMC article.

9.

Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review.

Lv X, Zhang PB, Zhang EL, Yang S.

World J Surg Oncol. 2025 Apr 26;23(1):166. doi: 10.1186/s12957-025-03765-7.

PMID: 40287734 Free PMC article. Review.

10.

Chronic Hepatitis B in the Transplant Setting: A 30-Year Experience in a Single Tertiary Italian Center.

Russo FP, Battistella S, Zanetto A, Gambato M, Ferrarese A, Germani G, Senzolo M, Mescoli C, Piano S, D'Amico FE, Vitale A, Gringeri E, Feltracco P, Angeli P, Cillo U, Burra P.

Viruses. 2025 Mar 21;17(4):454. doi: 10.3390/v17040454.

PMID: 40284897 Free PMC article.

11.

Achieving textbook outcome in liver resection for hepatocellular carcinoma: malnutrition's pivotal role.

Oji K, Urade T, Omiya S, Kido M, Komatsu S, Gon H, Fukushima K, Yanagimoto H, Toyama H, Fukumoto T.

Langenbecks Arch Surg. 2025 Apr 23;410(1):139. doi: 10.1007/s00423-025-03703-x.

PMID: 40266358 Free PMC article.

12.

Analysis of the survival of patients with hepatocellular carcinoma and indications for liver transplantation or hepatic resection.

Pinheiro RS, Fonseca GM, Andraus W, Coelho FF, Rocha-Santos V, Pirola Kruger JA, Waisberg DR, Jeismann V, de Martino RB, Ferrari Makdissi F, Ducatti L, Arantes Junior RM, Franca Bezerra RO, Rocha-Filho JA, de Souza Rocha M, Carneiro D'Albuquerque LA, Herman P.

BMC Surg. 2025 Apr 18;25(1):166. doi: 10.1186/s12893-025-02899-5.

PMID: 40251550 Free PMC article.

13.

Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.

Pomej K, Frick A, Scheiner B, Balcar L, Pajancic L, Klotz A, Kreuter A, Lampichler K, Regnat K, Zinober K, Trauner M, Tamandl D, Gasche C, Pinter M.

PLoS One. 2025 Apr 15;20(4):e0321189. doi: 10.1371/journal.pone.0321189. eCollection 2025.

PMID: 40233040 Free PMC article.

14.

Developing a novel predictive model for identifying risk factors associated with being lost to follow-up among high-risk patients for recurrence following radical resection of hepatocellular carcinoma: the first report.

Yu Z, Cao W, Du C, Liu J, Peng L, Wei F.

BMC Cancer. 2025 Apr 2;25(1):597. doi: 10.1186/s12885-025-14030-1.

PMID: 40175947 Free PMC article.

15.

Advances in radiation therapy for HCC: Integration with liver-directed treatments.

Yariv O, Newman NB, Yarchoan M, Rabiee A, Wood BJ, Salem R, Hernandez JM, Bang CK, Yanagihara TK, Escorcia FE.

Hepatol Commun. 2025 Mar 21;9(4):e0653. doi: 10.1097/HC9.0000000000000653. eCollection 2025 Apr 1.

PMID: 40163776 Free PMC article. Review.